[
  {
    "ts": null,
    "headline": "Earlier use of CARVYKTI® demonstrated lasting treatment-free remissions at 2.5 years in patients with relapsed or refractory multiple myeloma",
    "summary": "Johnson & Johnson (NYSE: JNJ) announced today updated results from the Phase 3 CARTITUDE-4 study supporting durable treatment-free remissions as early as second line treatment with CARVYKTI® (ciltacabtagene autoleucel; cilta-cel). In 80 percent of as-treated patients with relapsed or refractory multiple myeloma (RRMM) and standard-risk cytogenetics who were treated with CARVYKTI® as early as first relapse, the disease did not progress and no further treatment was required at 2.5 years (30 months",
    "url": "https://finnhub.io/api/news?id=814de370385704c4941ec6b8b7b086896ca0a967f44a3af52d6b47a1022c5199",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1765031400,
      "headline": "Earlier use of CARVYKTI® demonstrated lasting treatment-free remissions at 2.5 years in patients with relapsed or refractory multiple myeloma",
      "id": 137726351,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "JNJ",
      "source": "Yahoo",
      "summary": "Johnson & Johnson (NYSE: JNJ) announced today updated results from the Phase 3 CARTITUDE-4 study supporting durable treatment-free remissions as early as second line treatment with CARVYKTI® (ciltacabtagene autoleucel; cilta-cel). In 80 percent of as-treated patients with relapsed or refractory multiple myeloma (RRMM) and standard-risk cytogenetics who were treated with CARVYKTI® as early as first relapse, the disease did not progress and no further treatment was required at 2.5 years (30 months",
      "url": "https://finnhub.io/api/news?id=814de370385704c4941ec6b8b7b086896ca0a967f44a3af52d6b47a1022c5199"
    }
  },
  {
    "ts": null,
    "headline": "What New Catalysts Are Shaping the Evolving Narrative for Johnson and Johnson Now",
    "summary": "Johnson & Johnson’s latest narrative has tilted more constructive, with fresh research nudging its fair value estimate higher from about $200.82 to $202.54 per share and reaffirming a roughly 6.96% discount rate that underscores a steady risk return profile. Analysts are increasingly crediting portfolio simplification and improving growth drivers for this modest fair value upgrade, suggesting the market may be slowly reassessing the stock’s long term earnings potential. Stay tuned to see how...",
    "url": "https://finnhub.io/api/news?id=fc89d54f6d5da6e2bd3dbc2df8331ed2b4d64109a59547506a89cfbdf334fd8f",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1765008503,
      "headline": "What New Catalysts Are Shaping the Evolving Narrative for Johnson and Johnson Now",
      "id": 137726352,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "JNJ",
      "source": "Yahoo",
      "summary": "Johnson & Johnson’s latest narrative has tilted more constructive, with fresh research nudging its fair value estimate higher from about $200.82 to $202.54 per share and reaffirming a roughly 6.96% discount rate that underscores a steady risk return profile. Analysts are increasingly crediting portfolio simplification and improving growth drivers for this modest fair value upgrade, suggesting the market may be slowly reassessing the stock’s long term earnings potential. Stay tuned to see how...",
      "url": "https://finnhub.io/api/news?id=fc89d54f6d5da6e2bd3dbc2df8331ed2b4d64109a59547506a89cfbdf334fd8f"
    }
  },
  {
    "ts": null,
    "headline": "Jim Cramer on Bristol-Myers’ Recent Stock Gain: “Unbelievable”",
    "summary": "Bristol-Myers Squibb Company (NYSE:BMY) is one of the stocks Jim Cramer commented on along with the recent macro rally. Cramer mentioned the stock during the episode, as he commented: “Then it might be a comeback to the drug stocks. Why? Well, remember, lots of people think the economy is stalled or in a tailspin. They’re […]",
    "url": "https://finnhub.io/api/news?id=bc52093696b6b59f6be26d1592154b8348731c3f6857af29c20e123a2def2977",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1764999259,
      "headline": "Jim Cramer on Bristol-Myers’ Recent Stock Gain: “Unbelievable”",
      "id": 137715586,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "JNJ",
      "source": "Yahoo",
      "summary": "Bristol-Myers Squibb Company (NYSE:BMY) is one of the stocks Jim Cramer commented on along with the recent macro rally. Cramer mentioned the stock during the episode, as he commented: “Then it might be a comeback to the drug stocks. Why? Well, remember, lots of people think the economy is stalled or in a tailspin. They’re […]",
      "url": "https://finnhub.io/api/news?id=bc52093696b6b59f6be26d1592154b8348731c3f6857af29c20e123a2def2977"
    }
  },
  {
    "ts": null,
    "headline": "Dividend Champion, Contender, And Challenger Highlights: Week Of December 7",
    "summary": "Stay updated on Dividend Champions, Contenders, and Challengers. Review changes, ex-dividend, and pay dates.",
    "url": "https://finnhub.io/api/news?id=81d9840c52184ff00b18ae88dd7f70e73825caa975f17fd02baf431b26bd99c1",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1764981045,
      "headline": "Dividend Champion, Contender, And Challenger Highlights: Week Of December 7",
      "id": 137714648,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1072593728/image_1072593728.jpg?io=getty-c-w1536",
      "related": "JNJ",
      "source": "SeekingAlpha",
      "summary": "Stay updated on Dividend Champions, Contenders, and Challengers. Review changes, ex-dividend, and pay dates.",
      "url": "https://finnhub.io/api/news?id=81d9840c52184ff00b18ae88dd7f70e73825caa975f17fd02baf431b26bd99c1"
    }
  }
]